SG11201809678VA - [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor - Google Patents
[1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptorInfo
- Publication number
- SG11201809678VA SG11201809678VA SG11201809678VA SG11201809678VA SG11201809678VA SG 11201809678V A SG11201809678V A SG 11201809678VA SG 11201809678V A SG11201809678V A SG 11201809678VA SG 11201809678V A SG11201809678V A SG 11201809678VA SG 11201809678V A SG11201809678V A SG 11201809678VA
- Authority
- SG
- Singapore
- Prior art keywords
- grenzacherstrasse
- basel
- roche
- international
- hoffmann
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 title 1
- 108050007331 Cannabinoid receptor Proteins 0.000 title 1
- 102220240796 rs553605556 Human genes 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 244000061408 Eugenia caryophyllata Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 MEM 0 11101 HOE 010 1111 1 0 0101101011M 010 1111 1111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/220517 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, CO7D 487/04 (2006.01) A61P 11/00 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 31/519 (2006.01) A61P 33/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, A61P 29/00 (2006.01) A61P 35/00 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61P 25/00 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/EP2017/064994 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 20 June 2017 (20.06.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 16175924.6 23 June 2016 (23.06.2016) EP MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant (for all designated States except US): F. HOFF- KM, ML, MR, NE, SN, TD, TG). MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). Declarations under Rule 4.17: (71) Applicant (for US only): HOFFMANN-LA ROCHE — of inventorship (Rule 4.17(iv)) INC. [US/US]; Overlook at Great Notch, 150 Clove Road, Published: 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- — with international search report (Art. 21(3)) sey 07424 (US). — = = Inventors: GOBBI, Luca; c/o F. Hoffmann-La Roche (72) — AG, Grenzacherstrasse 124, 4070 Basel (CH). GRETHER, = Uwe; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). GUBA, Wolfgang; c/o F. Hoff- mann-La Roche AG, Grenzacherstrasse 124, 4070 Basel = _ (CH). KRETZ, Julian; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). MARTIN, Rain- er E.; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse = = 124, 4070 Basel (CH). WESTPHAL, Matthias; c/o Eidge- noessische Technische Hochschule Zuerich, Raemistrasse = = 101, 8092 Zuerich (CH). IJZERMAN, Adriaan Pieter; c/ o Leiden University, Rapenburg 70, 2311 EZ Leiden (NL). = = Agent: POMERANC, Didier; Grenzacherstrasse 124, 4070 Basel (CH). (74) = Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = Title: [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RE- (54) CEPTOR 1-1 ..11 1 (57) : The invention relates to a compound of formula (I) wherein R 1 to R 4 and N R— \ _ n are defined as in the description and in the claims. The compound of formula (I) can be ,N R 4 1-1 N used as a medicament. 1 1 in , , , 0 N N el N el (I) IN 1-1 © el n R 3 0
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16175924 | 2016-06-23 | ||
PCT/EP2017/064994 WO2017220517A1 (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809678VA true SG11201809678VA (en) | 2018-11-29 |
Family
ID=56203225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202113286RA SG10202113286RA (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
SG11201809678VA SG11201809678VA (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202113286RA SG10202113286RA (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
Country Status (24)
Country | Link |
---|---|
US (1) | US10457685B2 (en) |
EP (2) | EP4108665A1 (en) |
JP (2) | JP6962942B2 (en) |
KR (2) | KR102530131B1 (en) |
CN (4) | CN113943297A (en) |
AR (1) | AR108845A1 (en) |
AU (2) | AU2017283136C1 (en) |
BR (1) | BR112018075143A2 (en) |
CA (2) | CA3023043A1 (en) |
CL (1) | CL2018003610A1 (en) |
CO (1) | CO2018011231A2 (en) |
CR (2) | CR20220661A (en) |
IL (2) | IL292015B1 (en) |
MA (1) | MA45442A (en) |
MX (1) | MX2018014684A (en) |
MY (1) | MY197244A (en) |
PE (1) | PE20190109A1 (en) |
PH (1) | PH12018502733A1 (en) |
RU (1) | RU2741597C2 (en) |
SG (2) | SG10202113286RA (en) |
TW (2) | TWI824380B (en) |
UA (1) | UA123834C2 (en) |
WO (1) | WO2017220517A1 (en) |
ZA (1) | ZA201807133B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN109311886B (en) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives |
EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN113387845B (en) * | 2021-07-16 | 2022-12-20 | 国药集团化学试剂有限公司 | Preparation method of phenylmethylsulfonyl fluoride |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512326A (en) * | 1999-10-18 | 2003-04-02 | ユニヴァーシティ オブ コネチカット | Similar indole derivatives of cannabinoids |
JPWO2006051704A1 (en) * | 2004-11-15 | 2008-05-29 | 大正製薬株式会社 | Imine compounds |
EP1863778B1 (en) | 2005-03-31 | 2015-12-30 | Merck Sharp & Dohme Corp. | Spirocyclic thrombin receptor antagonists |
FR2887550A1 (en) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | New 1-benzylpyrazole-3-acetamide compounds are cannabinoids receptor antagonists useful to treat/prevent immune disorders, pain, gastrointestinal disturbances, cardiovascular/kidney disorders and in cancer chemotherapy |
MX2008012400A (en) * | 2006-03-30 | 2008-10-10 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity. |
US8629157B2 (en) * | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
CN102924457A (en) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | Triazolopyrimidine derivatives, preparation method and uses thereof |
UA111640C2 (en) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2 |
US9067943B2 (en) | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
PE20151539A1 (en) | 2013-03-07 | 2015-10-28 | Hoffmann La Roche | NEW DERIVATIVES OF PIRAZOLE |
EP2991988B1 (en) | 2013-05-02 | 2017-05-31 | F. Hoffmann-La Roche AG | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
KR102330794B1 (en) | 2013-05-02 | 2021-11-26 | 에프. 호프만-라 로슈 아게 | Purine derivatives as cb2 receptor agonists |
EP3483163B1 (en) * | 2013-09-06 | 2021-06-23 | F. Hoffmann-La Roche AG | Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists |
EP3215506B1 (en) | 2014-11-07 | 2019-01-02 | F.Hoffmann-La Roche Ag | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 |
WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN109311886B (en) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives |
EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
-
2017
- 2017-06-20 MY MYPI2018002797A patent/MY197244A/en unknown
- 2017-06-20 PE PE2018003112A patent/PE20190109A1/en unknown
- 2017-06-20 SG SG10202113286RA patent/SG10202113286RA/en unknown
- 2017-06-20 BR BR112018075143-0A patent/BR112018075143A2/en active Search and Examination
- 2017-06-20 SG SG11201809678VA patent/SG11201809678VA/en unknown
- 2017-06-20 UA UAA201900294A patent/UA123834C2/en unknown
- 2017-06-20 KR KR1020187037004A patent/KR102530131B1/en active IP Right Grant
- 2017-06-20 IL IL292015A patent/IL292015B1/en unknown
- 2017-06-20 KR KR1020237014572A patent/KR20230062680A/en not_active Application Discontinuation
- 2017-06-20 CA CA3023043A patent/CA3023043A1/en active Pending
- 2017-06-20 RU RU2018146657A patent/RU2741597C2/en active
- 2017-06-20 AU AU2017283136A patent/AU2017283136C1/en active Active
- 2017-06-20 CN CN202111184338.3A patent/CN113943297A/en active Pending
- 2017-06-20 CN CN202210799583.3A patent/CN115073476A/en active Pending
- 2017-06-20 CN CN202210807089.7A patent/CN115093418A/en active Pending
- 2017-06-20 JP JP2018566249A patent/JP6962942B2/en active Active
- 2017-06-20 MA MA045442A patent/MA45442A/en unknown
- 2017-06-20 WO PCT/EP2017/064994 patent/WO2017220517A1/en active Application Filing
- 2017-06-20 MX MX2018014684A patent/MX2018014684A/en unknown
- 2017-06-20 CA CA3206921A patent/CA3206921A1/en active Pending
- 2017-06-20 EP EP22174808.0A patent/EP4108665A1/en active Pending
- 2017-06-20 CR CR20220661A patent/CR20220661A/en unknown
- 2017-06-20 EP EP17731149.5A patent/EP3475282B1/en active Active
- 2017-06-20 CN CN201780036295.XA patent/CN109348716A/en active Pending
- 2017-06-20 CR CR20180615A patent/CR20180615A/en unknown
- 2017-06-21 AR ARP170101708A patent/AR108845A1/en unknown
- 2017-06-22 TW TW111101354A patent/TWI824380B/en active
- 2017-06-22 TW TW106120830A patent/TWI764908B/en active
-
2018
- 2018-10-19 CO CONC2018/0011231A patent/CO2018011231A2/en unknown
- 2018-10-25 ZA ZA2018/07133A patent/ZA201807133B/en unknown
- 2018-11-01 IL IL262711A patent/IL262711B2/en unknown
- 2018-12-14 CL CL2018003610A patent/CL2018003610A1/en unknown
- 2018-12-20 US US16/228,539 patent/US10457685B2/en active Active
- 2018-12-21 PH PH12018502733A patent/PH12018502733A1/en unknown
-
2021
- 2021-07-26 AU AU2021206925A patent/AU2021206925B2/en active Active
- 2021-10-14 JP JP2021168709A patent/JP7308246B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909344SA (en) | Anti-lag3 antibodies | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201809678VA (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | |
SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201804711RA (en) | Compounds and methods for kinase modulation, and indications therefor | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201900904PA (en) | Methods for cross coupling | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201807516UA (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar | |
SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
SG11201908127WA (en) | Method for producing multispecific antibodies | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |